San Diego-primarily based Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February immediately after revealing promising data from the mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as